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http://dx.doi.org/10.1016/j.ccr.2013.12.008SUMMARYCbx4 is a polycomb group protein that is also a SUMO E3 ligase, but its potential roles in tumorigenesis
remain to be explored. Here, we report that Cbx4, but not other members of the Cbx family, enhances hyp-
oxia-induced vascular endothelial growth factor (VEGF) expression and angiogenesis in hepatocellular car-
cinoma (HCC) cells through enhancing HIF-1a sumoylations at K391 and K477 in its two SUMO-interacting
motifs-dependent mechanisms and increasing transcriptional activity of HIF-1. The Cbx4 expression is
significantly correlated with VEGF expression, angiogenesis, and the overall survival of HCC patients and
also in subcutaneously and orthotopically transplanted mice HCC models. Collectively, our findings demon-
strate that Cbx4 plays a critical role in tumor angiogenesis by governing HIF-1a protein.INTRODUCTION
Polycomb group (PcG) proteins are major transcriptional repres-
sors that epigenetically modify chromatin (Morey and Helin,
2010; Mu¨ller and Verrijzer, 2009; Schwartz and Pirrotta, 2007).
PcG proteins are comprised of structurally diverse and function-
ally related proteins, many of which interact with each other to
form multimeric, chromatin-associated protein complexes. At
least two distinct polycomb repressive complexes (PRC),
PRC1 and PRC2, exist in mammals that exert important func-
tions in regulations of cell cycle, DNA repair, cell differentiation,
senescence, and death (Pirrotta, 1998; Sauvageau and Sauva-
geau, 2010). Consequently, dysregulations of genes encoding
PcG proteins, such as BMI1, CBX7, and EZH2, have been re-Significance
HIF-1, a key transcriptional factor to the cellular response to hy
esis of cancers and other diseases. Herein, we show that Cbx4
bywhichCbx4 increasesHIF-1 transactivation and thus govern
hepatocellular carcinoma (HCC) cells and transplanted HCCm
in a cohort of HCC patients. Collectively, Cbx4 exerts an impo
angiogenesis and maybe other HIF-1-related events. Reagen
beneficial for inhibiting tumor angiogenesis and treating other
118 Cancer Cell 25, 118–131, January 13, 2014 ª2014 Elsevier Inc.ported to be associated with tumorigenesis of many kinds of
cancers (Gil et al., 2005; Martin-Perez et al., 2010; Morey and
Helin, 2010). However, a clear picture of the exact regulatory
events of PcG complexes in cancers is hindered by themultiplic-
ity of PcG complexes and the distinct functions of PcG proteins.
Several polycomb chromobox (Cbx) proteins, including Cbx2,
Cbx4, Cbx6, Cbx7, and Cbx8, interact with the core PRC1 com-
plex and bind specifically with additional proteins with different
efficiencies (Vandamme et al., 2011). Besides being a member
of PRC1 complex, human Cbx4 (also known as polycomb 2,
Pc2) presents the small ubiquitin-related modifier (SUMO) E3
ligase activity. Recent analyses show that the chromodomain
in the N terminus and two SUMO-interacting motifs (SIMs)
of Cbx4 protein contribute to its polycomb- and SUMO E3poxia, promotes a series of events related to the pathogen-
interacts with and enhances sumoylation of HIF-1a protein,
s the hypoxia-induced VEGF expression and angiogenesis in
ice models. Cbx4 level is also correlated with overall survival
rtant role in HCC by controlling the activity of HIF-1 in tumor
ts targeting the SUMO E3 ligase activity of Cbx4 would be
hypoxia-related diseases.
Figure 1. Regulation of VEGF Expression by Cbx4 in HCC Cells
(A–F) Western blots for the indicated proteins (A and D); qRT-PCRmeasurement of the VEGFmRNA level (B and E); and ELISAmeasurement of the VEGF protein
level in the culture medium (C and F) in SMMC-7721 cells ectopically expressing Flag-tagged Cbx, Bmi1, or vehicle under hypoxia or normoxia for 12 hr as
indicated (A–C) or expressing one of the two pairs of Cbx4-specific shRNAs (shCbx4) or nonspecific shRNA (NS) under hypoxia or normoxia for 24 hr (D–F).
(G) The number of endothelial tubes formed byHUVEC cocultured with SMMC-7721 cells infectedwith the indicated shRNAs under normoxia or hypoxia for 16 hr.
Data are mean ± SD in triplicates in an independent experiment, which was repeated at least for three times with the same results.
See also Figure S1.
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Luis et al., 2011; Merrill et al., 2010). To date, only a limited reper-
toire of substrates for the SUMO E3 ligase activity of Cbx4 have
been identified, such as C terminus binding protein 1 (CtBP1)
(Kagey et al., 2003), DNA methyltransferase 3a (Dnmt3a) (Li
et al., 2007), Smad-interacting Protein 1(SIP1) (Long et al.,
2005), centrin-2 (Klein and Nigg, 2009), and homeodomain-inter-
acting protein kinase 2 (HIPK2) (Roscic et al., 2006).
Hepatocellular carcinoma (HCC) is the fifth most common
cancer and the third most common cause of cancer mortality
worldwide (El-Serag and Rudolph, 2007; Forner et al., 2012).
Over the past few years, there has been an explosion in our
understanding of the molecular alterations occurring in HCC,
and a series of molecular biomarkers that have potential prog-
nostic significance and may be therapeutic targets have been
identified (Feng, 2012; Iakova et al., 2011; Peng et al., 2009;
Zhao et al., 2012). It is believed that the most important aber-
rantly activated pathway is malignant angiogenesis (Zhu et al.,
2011), which is highlighted by the fact that HCC is a hypervascu-
lar tumor and that transarterial chemoembolization has become
an effective method to control HCC (Finn and Zhu, 2009; Forner
et al., 2012). It has been unveiled that important angiogenic
factors, especially vascular endothelial growth factor (VEGF),
are involved in the regulation of angiogenesis in HCC (Zhang
et al., 2012). VEGF or its receptor neuropilin-2 has been reported
to increase expressions of two members of PRCs, Ezh2 (Klauke
et al., 2013) and Bmi1 (Goel et al., 2012). Ezh2 was also reported
to promote tumor angiogenesis by methylating and silencing
vasohibin-1, an endothelial cell-specific and intrinsic negative
regulator of angiogenesis (Klauke et al., 2013; Smits et al.,
2011). However, it was unknown whether the members of
PRCs affect VEGF expression. Herein, we investigate Cbx4-
mediated regulation of VEGF expression and angiogenesis in
HCC cells and tissues.CRESULTS
Regulation of VEGF Expression by Cbx4 in HCC Cells
To address whether Cbx proteins affect VEGF expression, we
ectopically expressed several Flag-tagged members of Cbx
family and Bmi1, another component of PRC1, into HCC cell
line SMMC-7721 cells (Figure 1A) but found that none of these
affected the VEGF expression under normoxia (Figures 1B and
1C). Hypoxia is well documented to be implicated in the patho-
genesis of a broad range of hepatic diseases, including HCC,
and is one of the critical in vivo microenvironmental factors of
cancers (Hanahan and Weinberg, 2011; Kang and Pantel,
2013; Rosmorduc and Housset, 2010; Yang et al., 2013). Intrigu-
ingly, overexpression of Cbx4, but not of other Cbx members or
Bmi1, significantly increased VEGF expression under hypoxia
(1% oxygen) in several HCC cell lines (Figures 1B and 1C; Fig-
ures S1A–S1C available online).
To explore whether endogenously expressed Cbx4 con-
tributes to the regulation of VEGF expression, we knocked
down Cbx4 using two pairs of small hairpin RNA (shRNAs) that
effectively silenced endogenous Cbx4 expression (Figure 1D;
Figures S1D and S1E). Cbx4 silencing significantly inhibited
the hypoxia-induced VEGF expression (Figures 1E and 1F; Fig-
ures S1D and S1E). Moreover, the co-culture assay of SMMC-
7721 cells, together with human umbilical vein endothelial cells
(HUVEC), revealed that silencing Cbx4 in SMMC-7721 cells sup-
pressed the tube-forming ability of HUVEC under hypoxia (Fig-
ures 1G and S1F). All these data suggest that Cbx4 regulates
hypoxia-induced VEGF expression.
Correlation of Cbx4 with VEGF Expression and
Angiogenesis in HCC Tissues
Next, we assessed Cbx4 protein levels in tumor tissues from 727
cases of HCC patients (Table S1) by immunohistochemical (IHC)ancer Cell 25, 118–131, January 13, 2014 ª2014 Elsevier Inc. 119
Figure 2. Correlation of Cbx4 with VEGF and Angiogenesis in HCC tissues
(A–C) Representative IHC images of HCC samples for the low and high expressions of indicated proteins with nonrelated IgG as the negative control. The scale
bar represents 50 mm (A and B) or 100 mm (C).
(D–G) Box plots of VEGF (D) and MVD scores (F), and the percentages of tumors with high and low VEGF expressions (E) or MVD (G) in those with high (n = 464)
and low (n = 263) Cbx4 expressions. (D and F) Horizontal lines represent the median; the bottom and top of boxes, respectively, represent the 25th and 75th
percentiles; and the vertical bars represent the range of data. Any outliers are marked with a circle, and extreme cases are marked with an asterisk.
(H) Correlation analysis of relative mRNA levels of CBX4 and VEGF in fresh cancerous tissues from 23 HCC subjects.
See also Figure S2 and Table S1–S3.
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responded to Cbx4 in tumor cell lines and tissues (Figures S2A
and S2B). HCC tissues presented different degrees of immuno-
reactive scores (IRS; Figures 2A and S2C). Of the 727 specimen,
63.8% and 36.2% of tumors presented higher (IRS > 4) and no or
lower (IRS% 4) Cbx4 expressions, respectively. Considering the
in vitro findings that Cbx4 upregulated VEGF expression in HCC
cell lines, we also detected VEGF (Figures 2B and S2D) and
CD31 expressions (Figure 2C) by IHC staining, the latter being
indicated as microvessel density (MVD), and their correlations
with Cbx4 were analyzed in our greater cohort of HCC specimen.
The results demonstrated that Cbx4 expression had a significant
positive correlation with VEGF expression (Figures 2D and 2E;
Table S2) and MVD (Figures 2F and 2G; Table S3). We also
detected relative mRNA levels of VEGF and CBX4 in fresh tumor
tissues from an additional 23 cases of HCC patients by quantita-
tive real-time PCR, and a positive correlation betweenCBX4 and
VEGF mRNA levels could also be seen (Figure 2H).
Involvement of Two SIMs, but not Chromodomain, of
Cbx4 in VEGF Expression
The correlation of Cbx4 and VEGF expressions in HCC cell lines
and tissues prompted us to investigate how Cbx4 regulates hyp-
oxia-induced VEGF expression. Although other members of the
Cbx family had no effect on VEGF expression, we could not
exclude the possibility that Cbx4 regulates VEGF expression
through its polycomb-dependent function, because the presence
of distinct Cbx proteins confers target selectivity to PRC1 (Klauke120 Cancer Cell 25, 118–131, January 13, 2014 ª2014 Elsevier Inc.et al., 2013). To dissect the polycomb- and SUMO E3 ligase-
dependent functions of Cbx4, we created a F11A/W35L double-
mutation in its chromodomain (CDM) and three other mutants
with the deletions of SIM1 (DSIM1), SIM2 (DSIM2), or both
(DSIM1/2), as depicted in Figure 3A. We showed that all three
DSIMmutantsmaintained,whereasCDM lost, thepolycomb func-
tion, the latter being assessed by their interaction with H3K27Me3
(FigureS3A), amethyl-lysine onhistoneH3preferentially boundby
Cbx4 for its polycomb-dependent function (Fischle et al., 2003;
Luis et al., 2011). Unlike wild-type Cbx4 (Cbx4-wild-type [WT])
andCDM,DSIM1,andespeciallyDSIM2,had littleSUMOE3 ligase
activity on endogenous CtBP1 protein, a known substrate for
SUMO E3 ligase activity of Cbx4 (Kagey et al., 2003) (Figure S3B).
More intriguingly, the ectopic CDM expression still increased
hypoxia-induced VEGF production to a similar degree as Cbx4-
WT, whereas the ectopic expressions of all three SIMs-deleted
mutants failed to do so (Figures 3B–3D; Figures S1A–S1C). More-
over, Cbx4-WT and CDM, but not DSIM1/2, expressions in
SMMC-7721 cells also increased the hypoxia-induced tube-form-
ing ability of HUVEC in the co-culture assay (Figures 3E and S3C).
Collectively, both SIM1 and SIM2, but not polycomb-dependent
chromodomain of Cbx4, are required for their effects to enhance
hypoxia-induced VEGF expression in HCC cells.
Loss of Cbx4 Action on VEGF Expression in the Absence
of HIF-1
Hypoxia inducible factor-1 (HIF-1), consisting of an oxygen-sen-
sitive HIF-1a and constitutively expressed HIF-1b subunits, has
Figure 3. Action of Cbx4 and Its Mutants on Hypoxia-Induced VEGF Expression
(A) Schematic sketches of wild-type (WT) Cbx4 and its mutants used in the study.
(B–D)Western blots for the indicated proteins (B) and VEGFmRNA (C) and protein levels in the culturemedium (D) of SMMC-7721 cells ectopically expressing the
vehicle or expressing Flag-tagged WT or mutants Cbx4 under hypoxia or normoxia for 12 hr.
(E) The numbers of the endothelial tubes formed by HUVEC in the co-culture assay, together with SMMC-7721 cells transfected as indicated under normoxia or
hypoxia for 16 hr.
(F–K) Western blots for the indicated protein (F and G) and VEGFmRNA (H and I), and protein levels in the culture medium (J and K) in SMMC-7721 cells with or
without stable expression of the Flag-tagged Cbx4, together with nonspecific (NS) shRNA or with either of two pairs of HIF-1a or HIF-1b-specific shRNAs,
incubated under 12 hr of normoxia or hypoxia.
Data are mean ± SD in triplicates in an independent experiment, which was repeated at least for three times with the same results.
See also Figure S3.
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response to acute hypoxia. Hypoxia stabilizes HIF-1a protein,
which translocates into nuclei, where it forms the heterodimer
with HIF-1b and recognizes hypoxia-responsive elements
(HREs) in the promoters of its targeted genes, such as VEGF
(Harris, 2002; Semenza, 2012; Yuan et al., 2011). Therefore, we
asked whether HIF-1 is important for the Cbx4-increased
VEGF expression under hypoxia. Hence, we knocked down
HIF-1a or HIF-1b using two pairs of shRNAs for each (Figures
3F, 3G, S3D, and S3E). The HIF-1a or HIF-1b silencing almost
completely abrogated VEGF expression under 12 hr hypoxia.
Under these conditions, Cbx4 overexpression also failed to
increase VEGF expression (Figures 3H–3K; Figures S3F–S3I),
suggesting that HIF-1 is possibly required for Cbx4 action on
hypoxia-induced VEGF expression.CIncreased Activity of HIF-1 by Cbx4 in a SIM1- and SIM2-
Dependent Manner
The increased Cbx4 expression did not change HIF-1a protein
levels under hypoxia (Figures 1A, 3B, and 3F). We showed that
Cbx4-WT and CDM, but notDSIM1/2, overexpression increased
the expression of other HIF-1-targeted genes, whereas Cbx4
knockdown suppressed hypoxia-induced the expression of
other HIF-1-targeted genes, including erythropoietin (EPO),
pyruvate dehydrogenase kinase-1 (PDK1), and phosphoglyc-
erate kinase 1 (PGK1), besides VEGF (Harris, 2002; Semenza,
2012) in SMMC-7721 cells (Figures S4A and S4B). Based on
these facts, we speculated that Cbx4 regulates transcriptional
activity of HIF-1. For the convenience of transfection, human
293T cells were transfected with plasmids expressing HIF-1a
and/or Flag-tagged Cbx4, together with HRE-driven luciferase,ancer Cell 25, 118–131, January 13, 2014 ª2014 Elsevier Inc. 121
Figure 4. Cbx4-Increased Activity of HIF-1 and Roles of SUMO Isoforms
(A and B) Western blots and folds of the relative luciferase activity against lane 1 in human 293T cells transfected with pEF-BOS-HIF-1a (100 ng) and/or the
indicated doses of Flag-tagged Cbx4 (A), or pEF-BOS-HIF-1a (100 ng) and WT or mutants Cbx4 (100 ng) (B), together with pGL3-HRE-Luc and pSV40-renilla
for 24 hr.
(C and D) Flag-tagged Cbx4 (WT) and its mutants or Cbx4-specific shRNAs-infected SMMC-7721 cells were incubated under normoxia or hypoxia for 24 hr,
followed by ChIP with anti-HIF-1a antibody or nonrelated IgG. Precipitated DNAs were quantified by qRT-PCR for promoter (C) and nonpromoter (D) regions of
VEGF gene as depicted in the left scheme. The amounts of precipitated DNA were calculated as the percentage of the input sample.
(E) Western blots and folds of the relative luciferase activity against vehicle-transfected cells (lane 1) in human 293T cells transfected with pEF-BOS-HIF-1a
(100 ng) and Flag-tagged Cbx4 (100 ng), with the indicated doses of HA-tagged SUMO-1.
(F) Western blots and VEGF protein levels in the culture medium in SMMC-7721 cells transfected with pEF-BOS-HIF-1a (100 ng) and Flag-tagged Cbx4 (100 ng),
with the indicated doses of HA-tagged SUMO-1.
Data are mean ± SD of triplicates in an independent experiment, which were repeated at least for three times with the same results. See also Figure S4.
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Cbx4 Governs HIF-1a and Angiogenesis in HCCwith renilla as an internal control. The HIF-1a transfection
expressed the detectable HIF-1a protein under normoxia (Fig-
ure 4A). In this condition, Cbx4 dose dependently enhanced
HRE-driven luciferase activity (Figure 4A). The enhanced effect122 Cancer Cell 25, 118–131, January 13, 2014 ª2014 Elsevier Inc.still existed in the overexpression of CDM, but not in its three
SIMs-deleted mutants (Figure 4B).
We also performed chromatin immunoprecipitation (ChIP) to
test whether Cbx4 affects HIF-1a binding to the promoter of
Cancer Cell
Cbx4 Governs HIF-1a and Angiogenesis in HCCVEGF gene. Our results demonstrated that anti-HIF-1a antibody,
but not nonrelated immunoglobulin G (IgG), pulled down the
promoter rather than the nonpromoter region of VEGF gene in
hypoxia-incubated cells (Figures 4C and 4D). The overexpres-
sion of Cbx4-WT and CDM, but not DSIM1/2, remarkably
enhanced—whereas the silence of endogenous Cbx4 expres-
sion abrogated—the ability of HIF-1a binding to the promoter
of VEGF gene under hypoxia (Figures 4C and 4D). Notably,
both DSIM1 and DSIM2 also failed to enhance the DNA binding
ability of HIF-1a (see below; Figure 6B). All these data support
that Cbx4 increases the DNA-binding ability and thus transcrip-
tional activity of HIF-1 protein, for which both SIM1 and SIM2 of
Cbx4 are required.
Role of SUMOs for Cbx4 to Regulate Transcriptional
Activity of HIF-1
In light of our observations that, unlike Cbx4-WT and CDM, the
deletions of SIM1 and/or SIM2 of Cbx4 neither increased the
DNA-binding ability nor enhanced transcriptional activity of
HIF-1, we asked whether SUMOs have potential roles for Cbx4
to regulate the transcriptional activity of HIF-1a. In mammals,
there are mainly three functional SUMO isoforms with identical
structural folds, SUMO-1, 2 and 3, in which SUMO-1 only shares
44% sequence identity with SUMO-2, whereas SUMO-2 and3
are highly similar (88% identity) at the amino acid sequences (Su
and Li, 2002). Thus, we transfected HIF-1a and/or Flag-tagged
Cbx4, together with the different levels of hemagglutinin (HA)-
tagged SUMOs into 293T cells with the expressions of HRE-
luciferase as well as renilla as an internal control. The results
revealed that the ectopic expressions of all three SUMO isoforms
dose dependently elevated Cbx4-increased luciferase expres-
sion in the presence of HIF-1a expression (Figure 4E; Figures
S4C and S4D). In line with this, they also enhanced Cbx4-
increased HIF-1a-mediated VEGF production in SMMC-7721
cells (Figure 4F; Figures S4E and S4F).
Direct Interaction of Cbx4 with HIF-1a Protein through
Its SIM1
Considering that SIMs may also act as protein-interaction
modules that facilitate the formation of multiprotein complexes
in addition to playing possible roles in the sumoylation (Merrill
et al., 2010; Wotton and Merrill, 2007), we incubated the vehicle
or Flag-tagged Cbx4-infected SMMC-7721 cells under nor-
moxia or hypoxia for 24 hr, followed by the coimmunoprecipi-
tation (co-IP) with anti-HIF-1a antibody. Intriguingly, under
hypoxia, the antibody pulled down Flag-tagged Cbx4, as well
as HIF-1a and HIF-1b (Figure 5A). To address whether Cbx4
and HIF-1a interact with each other, the co-IP assays were
performed in human 293T cells with transient transfections of
GFP-tagged Cbx4 and/or Flag-tagged HIF-1a. The results
showed that anti-Flag antibody could pull down both Flag-
tagged HIF-1a and GFP-tagged Cbx4 (Figure 5B), which were
also coprecipitated by anti-GFP antibody (Figure 5C), suggest-
ing an interaction of HIF-1a and Cbx4. Furthermore, the gluta-
thione S-transferase (GST) pull-down assay supported a direct
interaction between Cbx4 and HIF-1a proteins (Figure 5D).
We also used anti-HIF-1a antibody to perform co-IP assays
in cell extracts from SMMC-7721 and HepG-2 cells incubated
under normoxia and hypoxia for 24 hr. As expected, anti-HIF-C1a, but not nonrelated IgG, pulled down endogenous Cbx4
protein in these hypoxia, but not normoxia-incubated. cells (Fig-
ure 5E). The in vitro co-IP assays with the recombinant proteins
and their fragments revealed that the Cbx4/HIF-1a interaction
required the N-terminal 1-602 amino acids of HIF-1a (Figure 5F)
and the N-terminal 1-288 amino acids of Cbx4 (Figure 5G), the
latter containing chromodomain and SIM1 of Cbx4 (Figure 3A).
Further analysis showed that anti-HIF-1a also effectively inter-
acted with CDM and DSIM2, besides Cbx4-WT, whereas the
interaction was abrogated in DSIM1 and DSIM1/2 (Figure 5H),
supporting that the SIM1 of Cbx4 contributes to its interaction
with HIF-1a protein.
HIF-1a Sumoylation by Cbx4 with Requirement of Its
SIM1 and SIM2
Based on our observations that the deletions of SIM1 and/or
SIM2 of Cbx4 failed to elevate, whereas ectopic expressions of
three SUMO isoforms enhanced the Cbx4-increased transcrip-
tional activity of HIF-1, we reasoned that Cbx4 promotes HIF-
1a sumoylation. Thus, we transfected GFP-tagged Cbx4 or
PIASy, a known SUMO E3 ligase for HIF-1a (Kang et al., 2010),
and/or SENP1 (sentrin/SUMO-specific proteases 1), a desumoy-
lated enzyme (Cheng et al., 2007), together with Flag-tagged
HIF-1a and HA-tagged SUMO-1 into 293T cells for 48 hr, fol-
lowed by co-IP assays with anti-Flag antibody. Consistent with
a previous report (Kang et al., 2010), PIASy stimulated HIF-1a
sumoylation (lane 6 versus lane 1, top, Figure 5I). Interestingly,
Cbx4 did dose dependently enhance HIF-1a sumoylation (lanes
1–4, top, Figure 5I), which was significantly decreased in the
presence of SENP1 (lane 5 versus lane 4, top, Figure 5I).
Further, SMMC-7721 cells with Cbx4 knockdown by its
specific shRNAs were incubated under normoxia or hypoxia,
followed by co-IP assays with anti-HIF-1a antibody. Our data
showed that a part of hypoxia-stabilized HIF-1a protein could
be sumoylated, which was significantly blocked by Cbx4
silencing (Figure 5J). Unlike the expression of Cbx4-WT and
CDM, the ectopic expression of all three SIMs-deleted mutants
could not stimulate hypoxia-stabilized HIF-1a protein modifica-
tion with SUMO-1 and SUMO-2/3 (Figure 5K). All these data indi-
cate that Cbx4 stimulates HIF-1a sumoylation, for which SIM1
and SIM2 are required.
Identification of Sumoylated Sites of HIF-1a Protein by
Cbx4
To consolidate the sumoylated action of Cbx4 on HIF-1a, the
in vitro sumoylation assay was performed. Because full-length
HIF-1a is too large to be purified from bacteria, we prepared
the recombinant SUMO3-His-tagged HIF-1a fragment 299-604
and incubated the fragment together with SUMO-1, E1 (SAE1/
SAE2), and E2 (Ubc9), as well as Cbx4 or PIASy. Consistent
with the previous reports that the SUMO-1, E1, E2 mixture could
directly sumoylate proteins (Kagey et al., 2003; Tatham et al.,
2003), the mixture alone produced modified HIF-1a bands in
the blot with anti-HIF-1a antibody (lane 3, top, Figure 6A), which
were confirmed as the sumoylated HIF-1a fragments by blotting
with an anti-SUMO-1 antibody (lane 3, bottom, Figure 6A). These
sumyolated bands, indicated with red lines, could be signifi-
cantly enhanced by Cbx4 (lane 2 versus lane 3, Figure 6A), but
not by PIASy (lane 4 versus lane 3, Figure 6A). On the contrary,ancer Cell 25, 118–131, January 13, 2014 ª2014 Elsevier Inc. 123
Figure 5. Interaction and Sumoylation of HIF-1a by Cbx4
(A) Western blots for the indicated proteins in the whole-cell lysates (input) and co-IP complex with anti-HIF-1a antibody in Flag-tagged Cbx4 or vehicle-infected
SMMC-7721 cells, which were incubated under normoxia or hypoxia for 24 hr.
(B and C)Western blots for the indicated proteins in the input and co-IP complex with anti-Flag (B) and anti-GFP antibodies (C) in 293T cells transfected with Flag-
tagged HIF-1a and/or GFP-tagged Cbx4 under hypoxia for 24 hr.
(D) Western blots for HIF-1a in GST pull-down complex (left panel) by recombinant GST alone or GST-tagged Cbx4 proteins (right panel) with the in vitro-
translated Flag-tagged HIF-1a protein from granulophilocyte system.
(E) Western blots for Cbx4 and HIF-1a in the input and co-IP complex with anti-HIF-1a antibody and nonrelated IgG in SMMC-7721 (left panel) and HepG-2 cells
(right panel) under normoxia or hypoxia for 24 hr.
(F and G) (Top) Western blots for Flag-tagged Cbx4 (F) or HIF-1a (G) in the co-IP complex with anti-His antibody from mixtures of the in vitro-translated Flag-
tagged Cbx4 proteins and three recombinant His-tagged HIF-1a fragments (F), or the in vitro-translated Flag-tagged HIF-1a with three His-tagged of Cbx4
fragments or vehicle (G). (Middle) Coomassie brilliant blue (CBB) staining on SDS-PAGE to show the amount of the arrows-pointed recombinant fragments from
the same reactions. (Bottom) The schematic representation of the HIF-1a or Cbx4 fragments. bHLH, basic helix-loop-helix domain; PAS, Per-ARNT-Sim domain;
ODD, oxygen-dependent degradation domain; TAD, transcriptional activation domain.
(H) Western blots for the indicated proteins in the input and co-IP complex with anti-Flag antibody in human 293T cells transfected by GFP-tagged Cbx4 (WT) or
its mutants, together with empty vector or Flag-tagged HIF-1a for 24 hr.
(I) Western blots for the indicated proteins in the input and co-IP complex with anti-Flag antibody in human 293T cells transfected with plasmids as indicated for
42 hr, followed by treatment of hypoxia for 6 hr.
(J and K) Western blots for the indicated proteins in the input and co-IP complex with anti-HIF-1a antibody in Cbx4-silencing (J) and the indicated plasmids-
transfected SMMC-7721 cells (K), which were incubated under normoxia or hypoxia for 6 hr.
All these experiments were repeated at least for three times with the same results.
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enhanced by PIASy (lane 4 versus lane 3, Figure 6A), but not
by Cbx4 (lane 2 versus lane 3, Figure 6A). These data suggest124 Cancer Cell 25, 118–131, January 13, 2014 ª2014 Elsevier Inc.that Cbx4 and PIASy sumoylated the fragment in different pat-
terns. Importantly, when lysines 391 and 477 were mutated
into arginines, Cbx4-enhanced sumoylated HIF-1a fragments
Figure 6. Promotion of HIF-1a Sumoylation by Cbx4 and Its Association with the Increased Transcriptional Activity of HIF-1a
(A)Western blots with anti-HIF-1a (top) and anti-SUMO-1 (bottom) antibodies in themixtures of recombinant SUMO3-His-tagged HIF-1a fragment (WT) or its K2R
mutant with the recombinant proteins as indicated. Bands indicated by red lines and green arrowhead, respectively, represented the Cbx4 and PIASy-enhanced
sumoylated HIF-1a fragments, and * represents nonspecific sumoylated proteins.
(B) ChIP assay with anti-Flag antibody in SMMC-7721 cells transfected with plasmids as indicated for 24 hr. Precipitated DNAs were quantified by qRT-PCR for
promoter regions of VEGF gene. The amounts of precipitated DNAwere calculated as the percentage of input sample. The symbols y and z represent comparison
with lanes 1 and 3, respectively.
(C) The VEGFmRNA level in SMMC-7721 cells transfectedwith plasmids as indicated for 24 hr and the VEGF protein level in the culturemedium of the same cells.
# and & represent comparison with lanes 2 and 4, respectively.
(D–G) ChIP-re-ChIP assays with the indicated antibodies in SMMC-7721 (D) and HepG-2 cells (E) under normoxia or hypoxia for 24 hr or Flag-HIF-1a-P2A Flag-
HIF-1a-P2A/K2R-transfected SMMC-7721 (F) and HepG-2 cells (G). Precipitated DNAs were quantified by qRT-PCR for promoter (top) and nonpromoter regions
(bottom) of VEGF gene.
(H) Cartoon shows a summary of our findings. We propose that Cbx4 interacts with HIF-1a protein via its SIM domain. Then Cbx4 stimulates HIF-1a sumoylation
at K391 and K477 by its SIM2-dependent SUMO E3 ligase activity, which increases transcriptional activity of HIF-1a/HIF-1b heterodimer, thus increasing VEGF
production and angiogenesis.
All data are mean ± SD of triplicates in an independent experiment. See also Figure S5.
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whereas PIASy-stimulated sumoylated HIF-1a fragments still
existed (lane 8 versus lane 4, Figure 6A). These results suggest
that Cbx4 enhances sumoylation of K391 and K477, whereas
PIASy might sumoylate HIF-1a on other lysines.CNo Effect of Cbx4 on Transcriptional Activity of K391/
K477-Mutated HIF-1a
To consolidate the association between the increased sumoyla-
tions and enhanced transcriptional activity of HIF-1a by Cbx4,
we transfected Flag-tagged HIF-1a-P2A (mutations of prolinesancer Cell 25, 118–131, January 13, 2014 ª2014 Elsevier Inc. 125
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Cbx4 Governs HIF-1a and Angiogenesis in HCC402 and 564 of HIF-1a into alanines to prevent its hydroxylation
and thus degradation under normoxia) (Semenza, 2012) or its
mutant Flag-tagged HIF-1a-P2A/K2R (mutations of K391 and
K477 into arginines based on HIF-1a-P2A) and/or GFP-tagged
Cbx4, its mutants, PIASy and/or SENP1 into SMMC-7721 cells.
Twenty-four hours later, ChIP assays were performed to monitor
DNA binding ability of HIF-1a-P2A and HIF-1a-P2A/K2R (Fig-
ure 6B), for which the specificity was shown in Figures S5A
and S5B. In line with the aforementioned observations, Cbx4-
WT or CDM (lanes 3 or 7 versus lane 1, Figure 6B), but none of
these SIMs-deleted mutants (lanes 4, 5, and 6 versus lane 1, Fig-
ure 6B), significantly enhanced the DNA-binding ability of HIF-
1a-P2A, which was abolished by SENP1 expression (lane 15
versus lane 3 or lane 16 versus lane 7, Figure 6B). Compared
with HIF-1a-P2A (lane 2 versus lane 1, Figure 6B), however,
HIF-1a-P2A/K2R had a much lower DNA-binding ability, which
was also not enhanced byCbx4 or by all of its fourmutants (lanes
9–13 versus lane 2, Figure 6B). HIF-1a-P2A and HIF-1a-P2A/
K2R had the similar DNA-binding ability in the presence of PIASy
(lane 8 versus lane 14, Figure 6B), and PIASy expression in-
hibited the DNA-binding ability of HIF-1a-P2A (lane 8 versus
lane 1, Figure 6B), which could be partially restored by SENP1
expression (lane 17 versus lane 8, Figure 6B), consistent with
the previous report (Kang et al., 2010). The similar results could
also be confirmed by VEGF expression (Figure 6C).
Recruitment of Cbx4 to Promoter of VEGF Gene,
Together with HIF-1a
We then asked whether Cbx4 is also recruited to the promoter
of VEGF gene, together with HIF-1a, by conducting a ChIP-re-
ChIP assay using anti-HIF-1a antibody for the first immunopre-
cipitation (IP), followed by anti-Cbx4 antibody for the second
IP (re-IP) cells under normoxia and hypoxia for 24 hr. As a
control, IP was also performed using anti-HIF-1a antibody, fol-
lowed by nonrelated IgG for the re-IP and using nonrelated
IgG, followed by anti-Cbx4 antibody as the re-IP. The promoter
and nonpromoter regions of VEGF gene, as depicted in Figures
4C and 4D, were quantified from the re-IP immunoprecipitates.
The results revealed that anti-Cbx4 antibody, but not nonrelated
IgG, could enrich the HIF-1a-bound promoter, but not nonpro-
moter, of VEGF gene in hypoxia-incubated cells (Figures 6D
and 6E), suggesting that endogenously expressed Cbx4 is
recruited to the promoter of VEGF gene, together with HIF-1a
protein, which could also be seen in hypoxia-incubated
SMMC-7721 cells with ectopic expression of Cbx4 (Figure S5C).
Further, we showed that Cbx4 interacted with HIF-1a-P2A and
HIF-1a-P2A/K2R to a similar degree (Figure S5D). We also per-
formed the ChIP-re-ChIP assays in SMMC-7721 and HepG-2
cells in the presence or absence of ectopic Flag-tagged HIF-
1a-P2A or HIF-1a-P2A/K2R expression, in which ChIP was per-
formed using anti-Flag antibody, followed by anti-Cbx4 antibody
for the re-ChIP, and nonrelated IgG was also used for controls.
The results showed that Cbx4 could bind the Flag-tagged HIF-
1a-P2A and HIF-1a-P2A/K2R-bound promoter of VEGF gene.
However, Cbx4-enriched HIF-1a-P2A/K2R binding to promoter
of VEGF gene was much lower than HIF-1a-P2A binding in these
two cell lines (Figures 6F and 6G). The same facts could also be
confirmed by ChIP-re-ChIP assays for ectopically expressed
GFP-tagged Cbx4 in SMMC-7721 cells (Figure S5E). Collec-126 Cancer Cell 25, 118–131, January 13, 2014 ª2014 Elsevier Inc.tively, these results further support that sumoylation enhance-
ment of HIF-1a at K391 and K477 is critical for its increased
transcriptional activity by Cbx4 (Figure 6H).
In Vivo Effects of Cbx4 on VEGF Expression,
Angiogenesis, and Metastasis
To assess the clinical relevance of Cbx4 expression, we
analyzed the survival of our cohort of HCC patients. Like VEGF
expression (Figure 7A), increased Cbx4 expression was signifi-
cantly correlated to the poorer overall survival (OS) with median
25 months versus 75 months, respectively, for patients with
higher and lower Cbx4 expressions of tumors (p < 0.001;
Figure 7B).
Finally, we focused on in vivo effects of Cbx4 and its two
mutants (CDM and DSIM1/2) on hepatoma xenografts. We sub-
cutaneously transplanted SMMC-7721 and MHCC97L cells with
or without stable expression of Cbx4 or its mutants into BALB/c
nude mice, and tumor growths were monitored by tumor vol-
umes. Although Cbx4 overexpression had no effect on the
in vitro growth of these two cell lines (Figures S6A and S6B),
tumors from subcutaneously transplanted cell lines with the
overexpression of Cbx4-WT and CDM mutant, but not DSIM1/
2 mutant, grew more rapidly compared with vehicle controls
(Figures 7C–7E; Figures S6C–S6E). IHC staining showed that
tumor cells still expressed Cbx4 or its mutants in tumor nodules.
In line with our in vitro findings, Cbx4-WT and CDM, but not
DSIM1/2, overexpression significantly increased VEGF expres-
sion and MVD in the transplanted tumor burdens (Figure 7F).
We also directly transplanted GFP-luciferase-labeled SMMC-
7721 cells stably expressing Cbx4 and its mutants or vehicle
into the livers of BALB/c nude mice. Luciferase photon fluxes
were monitored each week, and the representative noninvasive
bioluminescent images (BLI) at week 6 posttransplantation are
shown (Figure 8A). The results show that tumors with Cbx4-WT
andCDM, but notDSIM1/2, overexpression had higher luciferase
signals than those with vehicle infection (Figure 8B). After the
transplanted cells had grown for 6 weeks in situ, liver tumors
with Cbx4-WT and CDM overexpression were much bigger and
were more diffusely distributed into the whole liver than were
DSIM1/2 and vehicle-infected cells (Figures 8C and 8D). Further
histological analysis shows that orthotopically transplanted liver
tumors with Cbx4-WT and CDM overexpression also presented
higher MVDs and VEGF expression than did vehicle and DSIM1/
2-infected tumors (Figure 8E). Moreover, the numbers of lung
metastasis nodules in mice with Cbx4-WT and CDMoverexpres-
sionweresignificantly higher than thosewithvehicle andDSIM1/2
in the sixth week posttransplantation (Figures 8F and 8G).
Finally, we subcutaneously transplanted SMMC-7721 and
MHCC97L cells with or without knockdown of endogenous
Cbx4 by shRNAs into BALB/c nude mice. Although the in vitro
growth rate of these two cells with Cbx4 knockdown had no
different from vehicle (Figures S7A and S7B), the transplanted
tumors originated from Cbx4-silenced SMMC-7721 cells could
not be seen macroscopically within 4 weeks (Figure S7C).
Notably, more vessels were seen on vehicle-infected MHCC97L
cells-transplanted tumors and around which did not appear in
tumors with Cbx4-silencing cells (Figure 8H). MHCC97L cells
with Cbx4 knockdown produced significantly lower tumor
burden than did those with vehicle mice (Figures 8I and 8J). As
Figure 7. In Vivo Effects of Cbx4 on VEGF Expression and Angiogenesis
(A and B) Kaplan-Meier analysis of overall survival of 727 cases of HCC patients with high and low VEGF (A) or Cbx4 (B) level in their tumors. Marks on graph lines
represent censored samples.
(C–E) Female nudemice were subcutaneously injected into one side of ventral flankswith SMMC-7721 cells stably transfected with the vehicle, Cbx4 (WT), and its
mutants as indicated. The tumor volumes weremeasured every 4 days from day 14 after transplantation (C), and themacroscopic appearances (D) and weight (E)
of tumors at day 42 posttransplantation are shown.
(F) The representative IHC staining images (scale bars, 100 mm) and the expression scores of Cbx4 and VEGF and the numbers of MVD in SMMC-7721 cells-
originated tumors at day 42 after injection.
Data are mean ± SD in six mice in an independent experiment. # represents p < 0.01 compared with vehicle. See also Figure S6.
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could not show the effect of Cbx4 knockdown on lung metas-
tasis in orthotopically transplanted HCC model, but the silence
of Cbx4 did significantly inhibit tumor burden (Figures S7D and
S7E) and intrahepatic dispersion (Figures S7F and S7G).
DISCUSSION
Here, we report that Cbx4 increases hypoxia-induced VEGF
expression in HCC cells and that Cbx4 expression is highly
correlated with VEGF expression and angiogenesis in HCC tis-
sues, of which a great ratio expresses higher levels of Cbx4
protein. Like VEGF expression (Gadelhak et al., 2009; Kaseb
et al., 2011), the elevated Cbx4 protein has a positive correlation
with poor outcome in HCC patients. In line with these observa-
tions, we show that Cbx4 overexpression promotes, while
endogenous Cbx4 knockdown eliminates, VEGF production
and angiogenesis under hypoxia, and thus tumor progression
in subcutaneously and orthotopically transplanted HCC mice.
All these data suggest a role of Cbx4 in the pathogenesis of HCC.
Our further structure and effect relationship analyses reveal
that the SIMs-dependent, rather than polycomb-dependent,
function of Cbx4 contributes to its effect on enhanced hypox-
ia-induced VEGF expression and thus angiogenesis. It has
been well documented that the VEGF expression in the hypoxic
area of HCC can be induced by the HIF-1 (Pugh and Ratcliffe,
2003; Semenza, 2012). More intriguingly, Cbx4 increases tran-Cscriptional activity of HIF-1, although it fails to regulate HIF-1a
protein level, and the ectopic expressions of three SUMO iso-
forms significantly increase Cbx4-enhanced transcriptional
activity of HIF-1a, which is diminished by the desumoylated
enzyme SENP1 expression. Especially, Cbx4 directly interacts
with HIF-1a protein and enhances HIF-1a sumoylation. It has
been known that CtBP1 binds to the region beyond SIM1 and
SIM2 domains of Cbx4, and these two SIMs, especially SIM2,
mediate its sumoylated activity on CtBP1 (Merrill et al., 2010).
Our structure-effect relationship analyses show that the SIM1
of Cbx4 mainly mediate HIF-1a/Cbx4 interaction and that the
SIM2 was responsive for HIF-1a sumoylation by Cbx4. We
further identified the K391 and K477 of HIF-1a as sumoylated
sites for Cbx4. Although we could not exclude the possibility
that Cbx4 also stimulated sumoylations of other lysines, it did
not modulate the DNA-binding ability and transcriptional activity
of K391 and K477-mutated HIF-1a. Notably, Cbx4 could interact
with HIF-1a with these two lysines mutated to the similar degree
as thewild-type HIF-1a, and it was also recruited to the promoter
of VEGF gene, together with this HIF-1amutant, but this interac-
tion did not enhance the DNA binding ability and transcriptional
activity of the HIF-1a mutant. All these data suggest that Cbx4
contributes to enhanced transcriptional activity of HIF-1 through
sumoylation of HIF-1a at K391 and K477. Cbx4 does not influ-
ence the HIF-1a/HIF-1b heterodimeric formation, but the
Cbx4-increased transcriptional activity of HIF-1 was always
accompanied with the increased DNA-binding ability of HIF-1.ancer Cell 25, 118–131, January 13, 2014 ª2014 Elsevier Inc. 127
Figure 8. In Vivo Effects of Cbx4 on Tumor Invasion
GFP-luciferase-labeled Cbx4 (WT) and its two mutants-infected SMMC-7721 cells were orthotopically injected into livers.
(A) Four representative noninvasive BLI at day 42 after injection with the color scale depicting the photon fluxes emitted from the tumor cells.
(B) The photon fluxes (photons per second) at the indicated weeks postinjection.
(C) Four representative macroscopic observations of livers at day 42 postinjection.
(D) The numbers of tumor nodules in the liver under microscope at day 42 postinjection.
(legend continued on next page)
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Cbx4 Governs HIF-1a and Angiogenesis in HCCTherefore, we speculate that the HIF-1a sumoylations at K391
and K477 would modify its structure or recruit other proteins,
such as coactivator(s), to increase the DNA binding ability and
thus transcriptional activity of HIF-1a/HIF-1b heterodimer, which
remains to be further explored.
Previously, HIF-1a sumoylation was described by several
groups with conflicting results (Bae et al., 2004; Berta et al.,
2007; Carbia-Nagashima et al., 2007; Cheng et al., 2007), which
appear to vary from cell type to cell type (reviewed in Dimova and
Kietzmann, 2010; Nu´n˜ez-O’Mara and Berra, 2013). RSUME, an
RWD-containing sumoylation enhancer, was reported to
enhance the sumoylation of HIF-1a, promoting its stabilization
and transcriptional activity during hypoxia (Carbia-Nagashima
et al., 2007), whereas PIASy was shown to negatively regulate
hypoxia-induced HIF1a stability and transactivation (Kang
et al., 2010), the latter of which was confirmed in our experi-
mental system. Because it remains technically challenging to
directly map sumoylation sites (Nu´n˜ez-O’Mara and Berra,
2013), the sumoylation sites of HIF-1a by PIASy remains to be
identified. However, we show that Cbx4 and PIASy present a
different pattern for HIF-1a sumoylations and that PIASy does
not sumoylate the K391 and K477 of HIF-1a. Hence, we propose
that sumoylations of different lysines and different sumoylation
patterns by Cbx4 and PIASy might present their difference on
the stability and/or transcriptional activity of HIF-1a.
Cancer cells rely on angiogenesis to fulfill their need for oxygen
and nutrients. With an increasing understanding of the molecular
mechanisms of angiogenesis, agents targeting angiogenic
pathways and mediators have been investigated as potential
cancer drugs, and several anti-angiogenic drugs for cancer
have been approved over the past decade (Rapisarda and
Melillo, 2012; Weis and Cheresh, 2011). However, VEGF
blockade not only suppresses pathological angiogenesis but
also damages healthy vessels (Chen and Cleck, 2009; Okuno
et al., 2012). According to our results, increased expression of
Cbx4 is correlated with VEGF expression and angiogenesis in
HCC cells, suggesting that reagents targeting SUMO E3 ligase
activity of Cbx4 would be beneficial for inhibiting tumor angio-
genesis. On the other hand, HIF-1 also activates transcription
of many other genes besides VEGF that play key roles in critical
aspects of cancer biology (Koh and Powis, 2012; Semenza,
2012). Further investigation will be recruited to understand
whether increased Cbx4 expression contributes to other cancer
processes by regulating transactivation of HIF-1.
EXPERIMENTAL PROCEDURES
Cell Culture, Cloning Procedures, and Transfection
All cell lines were maintained in Dulbecco’s modified Eagle’s medium contain-
ing 1% penicillin and streptomycin, supplemented with 10% fetal bovine(E) The representative IHC staining images (scale bars, 100 mm) and the express
originated tumors at day 42 postinjection. # represents p < 0.01 compared with
(F) The number of lung metastasis nodules under microscope at day 42 postinje
(G) A representative hematoxylin and eosin staining image of lung metastasis nod
infected with shRNAs as indicated were subcutaneously injected into one side o
(H) The representative images show macroscopic observations of angiogenesis
(I) A photograph of mice after anesthesia at day 32 postinjection.
(J) A photograph of tumors at day 32 postinjection.
Data are mean ± SEM (B) or mean ± SD (D–F) of mice in the number indicated in
Cserum (FBS). One percent O2 was generated by flushing a 94% N2/5% CO2
mixture into the incubator. All expression plasmids are shown in the
Supplemental Experimental Procedures. For transient transfection, Lipofect-
amine 2000 transfection reagent was used following manufacturer’s protocol
(Invitrogen). Retroviruses were prepared by transient cotransfection with help-
er plasmids into 293T cells using Lipofectamine 2000.
Cohort
We obtained formalin-fixed and paraffin-embedded tumor specimens
of HCC patients, which were histopathologically diagnosed during January
2004 and December 2010 in the Department of Pathology, Affiliated Hospi-
tals of Youjiang Medical College for Nationalities and Guangxi Medical
University. All tumors were primary and were untreated before surgery.
Patients had been followed up to on October 31, 2011, and the correspond-
ing survival status was confirmed by means of patient or family contact. The
overall survival duration was defined from the date of surgical resection to
death or last known date alive. After giving written consent, demographic
and clinical data were collected in the hospitals using a standard interviewer
administered questionnaire and/or medical records, and detailed information
about them is described in the Table S1. Surgery-removed samples of all
cases were collected. Additionally, we also collected 23 fresh HCC
cancerous tissue specimens from Ren-Ji Hospital affiliated to Shanghai
Jiao Tong University School of Medicine, for analyzing Cbx4 and VEGF
mRNA expressions. These studies were approved, respectively, by the Med-
ical Ethical Committee of the Affiliated Hospitals, Youjiang Medical College,
and Ren-Ji Hospital, and informed consent was obtained from all subjects or
their relatives.
IHC
The protein expression levels of Cbx4 and VEGF were analyzed by IHC
with the corresponding anti-Cbx4 and anti-VEGF polyclonal antibody. Angio-
genesis was assessed using the IHC staining of anti-CD31 antibody for
human and mouse cancerous tissues. The stained slides were scored by
two investigators according to the value of IRS systems. Scores of Cbx4
and VEGF were divided into two classifications: low (IRS % 4) and high
(IRS > 4).
ELISA
VEGF concentration in cell culturemediumwas determined by ELISA using the
Human VEGF Quantikine ELISA Kit in accordance with the manufacturer’s
instructions (R&D Systems).
In Vitro Tube Formation
HUVEC and SMMC-7721 cells were seeded onto the solidified gel, and the
endothelial tubes were counted under photomicroscope.
In Vitro Sumoylation Assay
The assay was performed using sumoylation control kits (K007, LAE Biotech),
together with bacterially expressed SUMO3-His-tagged HIF-1a truncations
and Cbx4 or PIASy.
GST Pull-Down Assay
The purified GST or GST-tagged Cbx4 proteins were incubated with the trans-
lated HIF-1a protein for 2 hr at room temperature. Then the precipitations were
eluted by the SDS sample buffer and followed by western blot.ion scores of Cbx4 and VEGF and the number of MVD in SMMC-7721 cells-
vehicle.
ction.
ule (rounding by yellow line) from Cbx4-expressing cells.(H–J) MHCC97L cells
f ventral flanks of female nude mice.
of subcutaneous tumors in live mice at day 32.
the parenthesis. See also Figure S7.
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ChIP and ChIP-re-ChIP assays were performed with a Pierce Agarose ChIP
Kit (26156, Pierce Biotechnology) in accordance with the manufacturer’s
instructions. Precipitated DNAs were analyzed by qRT-PCR with the primers
in the promoter and nonpromoter regions of the VEGF gene.
qRT-PCR, shRNA, Luciferase Assay, Co-IP, and Western Blots
For details, see the Supplemental Experimental Procedures.
Animal Experiments
Animal care and experiments were performed in strict accordance with the
‘‘Guide for the Care and Use of Laboratory Animals’’ and the ‘‘Principles for
the Utilization and Care of Vertebrate Animals’’ and were approved by the
Experimental Animal Ethical Committee at Shanghai Jiao Tong University
School of Medicine. The detailed protocols are provided in the Supplemental
Experimental Procedures.
Statistical Analysis
All the statistical analyses were performed by the statistical package for social
science (SPSS) (v. 13) (SPSS Institute). The Wilcoxon-ranked sums test was
used to analyze the differences in the distributions of demographic character-
istics of patients between the two different Cbx4 expression groups. The
Pearson’s c2 test was used to evaluate the correlation between Cbx4 expres-
sion and VEGF expression or MVD. The correlation of relative mRNA levels of
Cbx4 and VEGF in fresh cancerous tissuewas analyzed using linear correlation
and regression. Kaplan-Meier survival analysis with the log-rank test was used
to evaluate the relationship between Cbx4 or VEGF expression and HCC prog-
nosis. The p values for comparison between line-linked groups were obtained
by Student’s t test. All statistical tests were two-sided, and p < 0.05 was
considered to be statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.12.008.
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